公开(公告)号：US20220378799A1

公开(公告)日：2022-12-01

申请号：US17616571

申请日：2020-06-05

Applicant: BEIJING TIDE PHARMACEUTICAL CO., LTD.

Inventor： Yanping Zhao ,  Hongjun Wang ,  Bin Liu ,  Yuanyuan Jiang ,  Weiting Zhong ,  Huifen Xu ,  Honglei Zhang ,  Chuangchuang Huang ,  Nana Tian ,  Jing Zhao ,  Jing Li ,  Weina Liu ,  Liying Zhou ,  Yanan Liu

IPC: A61K31/5377 ,  C07D471/04 ,  C07D413/14 ,  A61P35/00

Abstract: Compounds of general formula (A) can be used for treating ATR kinase-mediated diseases, for example, hyperplastic diseases such as cancers. Also provided are a pharmaceutical composition of the compounds of general formula (A), a use of the pharmaceutical composition for treating the ATR kinase-mediated diseases and a preparation method for the pharmaceutical composition.

公开(公告)号：US20220378743A1

公开(公告)日：2022-12-01

申请号：US17435061

申请日：2020-02-26

Applicant: BEIJING TIDE PHARMACEUTICAL CO., LTD.

Inventor： Yuanyuan JIANG ,  Weiting ZHONG ,  Yanping ZHAO ,  Hongjun WANG ,  Jing ZHAO ,  Jing Li ,  Weina LIU ,  Liying ZHOU ,  Yanan LIU

IPC: A61K31/416 ,  A61K31/343 ,  A61K9/06 ,  A61K9/08 ,  A61P3/04

Abstract: The present invention falls within the field of biological medicine, and specifically relates to a method for preventing, alleviating and/or treating fatty liver disease and/or steatohepatitis. The method comprises administering, to an individual in need thereof, an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt, an ester, a stereoisomer, a polymorph, a solvate, an N-oxide, an isotopically labeled compound, a metabolite or a prodrug thereof.

公开(公告)号：US20230271968A1

公开(公告)日：2023-08-31

申请号：US18016164

申请日：2021-07-13

Applicant: BEIJING TIDE PHARMACEUTICAL CO., LTD.

Inventor： Cheung Ling Cheng ,  Yanping Zhao ,  Hongjun Wang ,  Bin Liu ,  Weiting Zhong ,  Huifen Xu ,  Chuangchuang Huang ,  Jing Li ,  Weina Liu

IPC: C07D487/04 ,  A61P35/00

CPC classification number: C07D487/04 ,  A61P35/00

Abstract: Disclosed is a compound of a general formula (I), which may be used for the treatment of ATR kinase-mediated diseases, for example, proliferative diseases such as cancer. Further disclosed are a preparation method for the compound of the general formula (I), a pharmaceutical composition, and use of the pharmaceutical composition for the treatment of ATR kinase-mediated diseases.